ArticleCureus2026
Unmasking the Myositis: A Diagnostic Clue to Occult Breast Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterised by proximal muscle weakness and pathognomonic cutaneous features. A well-recognised but underappreciated association exists between DM and underlying malignancy, termed cancer-associated myositis (CAM). The prevalence of malignancy in DM patients is high, with breast, ovarian, lung, and gastrointestinal cancers most commonly implicated. However, the detection of occult malignancy in young women presenting with DM remains particularly challenging due to atypical epidemiology and the limitations of standard imaging in dense breast tissue. This report presents the case of a woman in her third decade who was initially diagnosed with idiopathic DM based on heliotrope rash, Gottron papules, proximal limb weakness, elevated creatine phosphokinase (CPK), and serological positivity for anti-Mi-2 antibody. Despite the initiation of corticosteroids and methotrexate, the patient showed clinical deterioration over four weeks. Discovery of a firm left axillary lymph node on physical examination prompted further workup. Axillary node biopsy confirmed metastatic estrogen receptor-positive(ER+)/progesterone receptor-positive (PR+)/human epidermal growth factor receptor 2 (HER2)-neu+ breast adenocarcinoma. Conventional mammography and breast ultrasonography had been negative, while breast MRI identified a 1.8 mm lesion in the lower inner quadrant. Fluorodeoxyglucose (FDG)-PET/CT confirmed locoregional disease without distant metastasis. Following neoadjuvant chemotherapy, surgery, and radiation, the patient achieved complete remission of her myositis, with normalisation of creatine phosphokinase (CPK) levels, resolution of rash, and recovery of muscle strength, confirming the paraneoplastic aetiology. This case underscores the imperative to pursue malignancy screening in DM patients unresponsive to immunosuppressive therapy, regardless of age. It highlights the critical role of thorough physical examination and the superiority of breast imaging in young women with dense breasts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.